News

Biotechnology company Liberate Bio, Inc. has secured new intellectual property licenses aimed at advancing next-generation cell therapies that reprogram immune cells directly inside the…
Read More...

Biotechnology companies Akeso, Inc. and INOVIO have announced a clinical trial collaboration and supply agreement to evaluate a new combination immunotherapy approach for glioblastoma…
Read More...

Clinical-stage biotechnology company Tenaya Therapeutics has announced a new research collaboration with RNA interference specialist Alnylam Pharmaceuticals aimed at identifying novel…
Read More...

BioMed Realty has announced that CordenPharma Colorado has signed a long-term lease for a new laboratory facility at Flatiron Park in Boulder, marking a significant expansion for the…
Read More...

Affinia Therapeutics has received Fast Track designation from the U.S. Food and Drug Administration for its investigational gene therapy candidate AFTX-201, a potential treatment for…
Read More...

Innovative biotech firm Antengene Corporation Limited has entered into a major global licensing agreement with biopharmaceutical company UCB to advance the development of ATG-201, a…
Read More...

Esperion has announced a definitive agreement to acquire Corstasis Therapeutics in a move aimed at strengthening its cardiovascular portfolio and expanding access to innovative…
Read More...

The Ministry of Health, Labour and Welfare has granted orphan drug designation to rilzabrutinib, an investigational oral therapy, for the treatment of IgG4-related disease (IgG4-RD).…
Read More...

Pharmaceutical giant Novo Nordisk has announced a €432 million investment to expand its manufacturing facility in Athlone, Ireland, a move aimed at increasing production capacity for…
Read More...

Biotechnology company Sinopia Biosciences, Inc. has entered into a research collaboration with Japanese pharmaceutical firm Ono Pharmaceutical Co., Ltd. to discover new therapeutic…
Read More...

Quotient Sciences has announced an extended commercial supply partnership with Ipsen to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare and…
Read More...

GSK plc has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted for review a new drug application for bepirovirsen, an investigational antisense…
Read More...

GSK plc has announced that China’s drug regulator has accepted its new drug application for linerixibat to treat cholestatic pruritus in patients with primary biliary cholangitis (PBC),…
Read More...

Novo Nordisk and Vivtex Corporation have announced a strategic partnership to develop next-generation oral biologic medicines targeting obesity, diabetes and related metabolic…
Read More...

IQVIA Holdings Inc. has entered into an agreement to acquire certain drug discovery services assets from Charles River Laboratories, a move designed to expand its early-stage research…
Read More...

Japanese industrial giant Asahi Kasei has agreed to acquire German biopharmaceutical firm Aicuris Anti-infective Cures AG for about €780 million (roughly $919 million), a deal aimed at…
Read More...

NorthX Biologics and Demeetra have announced a strategic collaboration aimed at streamlining biologics development and accelerating biotech companies’ progress toward investigational…
Read More...

Slate Medicines, Inc. has emerged from stealth with $130 million in Series A financing and the in-licensing of a promising migraine therapy, positioning the company to compete in the…
Read More...

GSK plc announced that ViiV Healthcare has reported positive 12-month interim results from its phase IIb EMBRACE study, highlighting the potential of an ultra long-acting HIV treatment…
Read More...

GSK plc has agreed to acquire 35Pharma Inc., a privately held Canadian biopharmaceutical company focused on protein-based therapeutics. The deal brings into GSK’s pipeline HS235, an…
Read More...